Who Paid My Doc
Jonathan Staben
Family Medicine Cheney, WA Medical Doctor
NPI 1720071889 CMS profile 169173
19 N 7Th St, Cheney, WA 99004
General payments
$9,116
Research payments
$316
Ownership & investment interest
$0
Research they led as principal investigator
$2,482,934
Through program year 2024, Jonathan Staben of Cheney, WA is reported in the CMS Open Payments database as having received $9,116 across 27 general payments and $316 in research payments paid to them. Separately, studies naming them as principal investigator received $2,482,934 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | Research | $316 | 1 | |
| 2021 | General | $1,025 | 2 | |
| 2020 | General | $7,998 | 23 | |
| 2019 | General | $93 | 2 |
Beside peers
- Jonathan Staben
- Family Medicine median
- Middle half of Family Medicine
- National median
In program year 2025, general payments to Jonathan Staben were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.
Show as a table
| Year | Jonathan Staben | Family Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $93 | $150 | $41–$543 | $163 |
| 2020 | $7,998 | $120 | $32–$415 | $114 |
| 2021 | $1,025 | $137 | $35–$551 | $132 |
| 2022 | $0 | $137 | $37–$512 | $149 |
| 2023 | $0 | $149 | $42–$545 | $160 |
| 2024 | $0 | $156 | $44–$560 | $164 |
| 2025 | $0 | $155 | $45–$549 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 107 drugsPart D claims
5,086
Drug cost
$344,932
Branded share of claims
20%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 44 | $70,820 | |
| Ozempic Semaglutide | Brand | 35 | $52,218 | |
| Eliquis Apixaban | Brand | 37 | $46,744 | |
| Xarelto Rivaroxaban | Brand | 20 | $24,535 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 18 | $17,229 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 13 | $15,809 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 44 | $10,804 | |
| Advair Hfa Fluticasone Propion/Salmeterol | Brand | 22 | $10,086 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 17 | $9,013 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 35 | $8,561 |
The 10 drugs with the highest cost, of 107 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 37 billing codesPaid by Medicare
$70,044
Medicare patients
257
Services billed
2,818
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 62% | |
| Arthritis | 33% | |
| Diabetes | 23% | |
| Ischemic heart disease | 19% | |
| COPD | 18% | |
| Chronic kidney disease | 17% | |
| Atrial fibrillation | 16% | |
| Heart failure | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Sarscov2 vac 50 mcg/0.5ml im 91322 | Office | 14 | 15 | $2,268 |
| Vaccine for influenza for injection into muscle 90662 | Office | 21 | 21 | $1,718 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
28 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Family Medicine in Washington
Related records
Family Medicine in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Family Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.